Trans-RosaLEE Study: a Biomarker-directed, Translational Study

NARecruitingINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

October 1, 2027

Conditions
Advanced or Metastatic Breast Cancer (BC)
Interventions
GENETIC

Pre-treatment biopsy

Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET

GENETIC

Post treatment biopsy

Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.

GENETIC

Pre treatment blood sampling

Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)

GENETIC

Post treatment blood sampling

Sampling of 2 Streck tubes (10ml)

Trial Locations (1)

Unknown

RECRUITING

Institut Paoli Calmettes, Marseille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Institut Paoli-Calmettes

OTHER